St. Louis Startup That Aids With Alzheimer’s Testing Receives $20M Investment

Local St. Louis startup, C2N Diagnostics, received a $20 million investment from a Minneapolis-based foundation. This new funding from the GHR Foundation will allow C2N to build a clinical laboratory testing facility in St. Louis. The GHR Foundation was started by Gerald and Henrietta Rauenhorst with a mission to support Alzheimer’s research.

C2N Diagnostics is currently developing a commercial blood test for Alzheimer's disease and brain amyloid. C2N is pioneering novel, intelligent ways to develop drugs against brain disorders at a more rapid pace and lower cost than conventional methods. In addition, they are commercializing point-of-care diagnostics to enable early detection of conditions like Alzheimer’s disease. They also hope to have blood test available soon for patients showing early signs of dementia.

C2N’s testing is based on research conducted by professors at local college, Washington University. The methods that C2N uses are highly sensitive, target validated, quick, and low cost, which makes their science stand out from others. Their therapeutic discovery efforts are focused around mechanism-based approaches to prevent or stop the progression of human neurological disorders. Some of the company’s partners include AbbVie, Cambridge Isotope Laboratories and the National Institute of Aging.